CBRN Medical Countermeasures Workshop 2009
Videocast of Plenary Sessions
Day One: June 25,2009 | Day Two: June 26,2009 |
Opening Remarks and Overview of Strategic Plan and CBRN Division |
8:30 - 9:30AM |
8:30 - 8:40 am Welcome and Opening Remarks - Dr. Carol Linden
HHS, Principal Deputy Director of the Biomedical Advanced Research and Development Authority, BARDA
8:40 - 8:50 am Overview of BARDA and the CBRN Division - Dr. Gary Disbrow
Deputy Director, CBRN Division of Countermeasures, BARDA
8:50 - 9:00 am Overview of CBRN Strategic Plan - Dr. Gerald Kovacs
Director, CBRN Division Countermeasures, BARDA
Programmatic Presentations by BARDA Staff |
9:00 - 10:15 AM |
9:00 - 10:00 am Programmatic Presentations by BARDA Staff
- Anthrax Vaccines - Dr. Narayan Iyer, Chief Anthrax Vaccines
- Antitoxins - Dr. Stephen Morris, Chief, Anthrax Therapeutics
- Chem/Rad/Nuc - Dr. Ronald Manning, Chief Chemical Radiological Nuclear Countermeasures
- Smallpox - Dr. Dawn Myscofski, Chief Smallpox Vaccines
- SSTD - Dr. Jerome Donlon, Director Strategic Science and Technology Division
10:00 - 10:15 am Panel Q&A with Directors and Branch Chiefs
Online Resources and Requirements Generation |
10:30-11:30 AM |
10:30 - 10:40 am Overview of Medical Countermeasures Website and Navigation -
Ms. Elizabeth Jarrett, Program Analyst, BARDA
10:40 - 11:15 am Requirements Generation
- Department of Homeland Security - Dr. Diane Berry - Chief Scientist, Office of Health Affairs, DHS
- Policy Planning and Requirements for BARDA - Dr. Joanna Prasher - Rad/Nuc Policy Planning and Requirements, BARDA
- BARDA Modeling Group - Ms. Mary Beth Hill-Harmon - Program Analyst, Modeling, BARDA
11:15 - 11:30 am Panel Q & A with Presenters
Integrated National Biodefense Portfolio and Funding Mechanisms |
10:30-11:30 AM |
11:30 - 12:30 pm Overview of Integrated National Biodefense Portfolio - Dr. Carol Linden - Principal Deputy Director, BARDA
Funding Mechanisms and Roles in Development of Medical Countermeasures
- Dr. Albert Churilla, Chief, Medical Science and Technology
Division,
Chemical / Biological Technologies Directorate, Joint Science & Technology Office Defense Threat Reduction Agency - Dr. Helen Schiltz, Acting Chief, Drug Development
Section,
Office of Biodefense Research Affairs, Division of Microbiology and Infectious Diseases, NIAID, NIH
12:30 -12:45 pm Q & A
The Regulatory Pathway and Closing Remarks |
2:00 - 3:30 PM |
2:00 - 3:00 pm Regulatory Issues, Critical Path and Lessons Learned
- Animal Rule - Dr. Rosemary Roberts
Director, Office of Counterterrorism and Emergency Coordination, Center for Drug Evaluation and Research, FDA - EUA and Contingency Use - Dr. Debra
Yeskey
Director, Regulatory and Quality Affairs Division, BARDA - SNS and Their Role in Stockpiling &
Deployment - Dr. Susan Gorman
Division of Strategic National Stockpile, CDC - Critical Path and Lessons Learned -
Dr. Thomas Dreier - Subject Matter Expert, BARDA/CBRN
Dr. Michael Merchlinsky - Subject Matter Expert, BARDA/CBRN
Mr. David Aglow - Subject Matter Expert, BARDA/CBRN
3:00 -3:15 pm Panel Q & A
3:15 -3:30 pm Closing Remarks and Wrap
Up - Dr. Gerald Kovacs
Director, CBRN Division Countermeasures